CytoDyn Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-42.7M | $3.7M | $-49.8M | $-79.8M | $-210.8M | $-176.5M | $-139.9M | $-56.2M |
| Depreciation & Amortization | $17.0K | $18.0K | $29.0K | $175.0K | $781.0K | $1.8M | $2.0M | $1.2M |
| Depreciation | — | — | $29.0K | $43.0K | — | — | — | — |
| Amortization | — | — | — | $100.0K | $700.0K | $1.8M | $2.0M | $1.2M |
| Stock-Based Compensation | $1.6M | $1.6M | $2.4M | $4.3M | $6.2M | $10.4M | $6.5M | $3.4M |
| Net Cash from Operating Activities | $-17.3M | $-8.8M | $-11.0M | $-25.1M | $-77.7M | $-117.6M | $-68.8M | $-50.5M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | $122.0K | $41.0K | $26.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $0 | — | — | — | $-122.0K | $-41.0K | $-45.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $17.2M | $10.9M | $11.7M | $29.9M | $48.0M | $137.3M | $79.7M | $52.7M |
| Net Change in Cash | $-51.0K | $2.1M | $766.0K | $4.8M | $-29.7M | $19.7M | $10.8M | $2.2M |
| Free Cash Flow | — | — | — | — | — | $-117.7M | $-68.8M | $-50.5M |